ProCE Banner Activity

Next-Generation Endocrine Therapies for ER+/HER2- Breast Cancer Care: Key Takeaways From Our Recent Symposium in San Antonio

Clinical Thought

Get up to date with experts’ key takeaways on next-generation endocrine therapies for ER-positive/HER2-negative breast cancer, including guidance on ESR1 mutation testing, use of oral SERDs in patients with ESR1 mutations, and other endocrine therapies on the horizon.

Released: December 20, 2023

Share

Faculty

Erika P. Hamilton

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Chair, Breast Executive Committee
Sarah Cannon Research Institute
Nashville, Tennessee

Kevin Kalinsky

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Disclosure

Primary Author

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Chair, Breast Executive Committee
Sarah Cannon Research Institute
Nashville, Tennessee

Erika P. Hamilton, MD: researcher (paid to institution): AbbVie, Acerta , Accutar, ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss BioPharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Cascadian, Clovis, Compugen, Context, Cullinan, Curis, CytomX, Daiichi Sankyo, Dana-Farber Cancer Institute, Dantari, Deciphera, Duality Biologics, eFFECTOR, Eisai, Ellipses Pharma, Elucida Oncology, EMD Serono, Fochon, FujiFilm, G1 Therapeutics, Gilead, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity, Inspirna, InventisBio, Jacobio, Karyopharm, K-Group Beta, Kind, Leap, Lilly, Loxo Oncology, Lycera, MabSpace Biosciences, MacroGenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Myriad Genetic Laboratories, Novartis, Nucana, Olema, OncoMed, Oncothyreon, ORIC, Orinove, Orum, Pfizer, PharmaMar, Pieris, Pionyr Immunotherapeutics, Plexxikon, Prelude, Profound Bio, Radius Health, Regeneron, Relay, Repertoire Immune Medicine, Rgenix, Roche/Genentech, SeaGen, Sermonix, Shattuck Labs, Silverback, StemCentRx, Stemline, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque, Treadwell, Verastem, Zenith Epigenetics, Zymeworks; consultant/advisor (paid to institution): Accutar, Arvinas, AstraZeneca, Circle, Daiichi Sankyo, Entos, Gilead, IQVIA, Janssen, Jazz, Jefferies, Johnson & Johnson, Lilly, Medical Pharma Services, Mersana, Olema, Pfizer, Roche/Genentech, Shorla, Stemline, Tempus Labs, Theratechnologies, Tubulis, Zentalis.

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Kevin Kalinsky, MD, MS: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Genentech/Roche, Immunomedics, Menarini, Mersana, Merck, Myovant, Puma Technology, Seattle Genetics, Silicon Biosystems, Takeda.